I also have a question for our friends from the Department of Industry, Trade and Commerce.
At the beginning of the pandemic, the pharmaceutical community was clear on one thing, namely that, over the past five years, there had been no adequate policy. In fact, there had apparently been even a certain indifference. Witnesses who appeared before us said the same thing.
Can you tell us why players in the field feel this way?
What was done in the five years prior to the pandemic? I recall the pharmaceutical companies saying that they were not able to work with the community to hear its needs.
Was the idea to rebuild a pharmaceutical sector before the crisis?